PharmaTelevision - BiondVax Pharmaceuticals Ltd: Wayne Rudolph explains their focus on development of a Universal Influenza vaccine.

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: BiondVax Pharmaceuticals Ltd: Wayne Rudolph explains their focus on development of a Universal Influenza vaccine.

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Wayne Rudolph, Vice President of Corporate Development of BiondVax Pharmaceuticals Ltd.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Focus on development of Universal Influenza vaccine

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BIO 2011 in Washington DC. On this show I have Wayne Rudolph, who is Vice President and Corporate Development at a company called BiondVax , which is based just outside Tel-Aviv in Israel, welcome to the show.

Wayne Rudolph:

Thank you very much for having me.

Fintan Walton:

BiondVax , I think is an interesting company obviously the word vax is a little indication of where your focus, but first of all tell us about the company, it's foundation and how it's currently funded?

Wayne Rudolph:

Sure, we are a small biotech company based in Ness Ziona in Israel. We are a spin-off from the Weizmann Institute, which is one of Israel's premier scientific academic institutions, we are very uniquely focused on the development of the universal influenza vaccine. So we ultimately aim to bring a product to market that is a vaccine, that is protective against all strains of flu no matter if it's a seasonal flu or pandemic flu and hopefully one shot that will cover you for a number of years and that's our focus.

Fintan Walton:

So quite an important one, because obviously the flu vaccine the universal flu vaccine has been an objective for many, many years and this to achieve this would have a huge impact on human health?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Wayne Rudolph

Vice President

Wayne Rudolph currently serves as Vice President Corporate Development at BiondVax Pharmaceuticals. Prior to joining BiondVax in October 2009, Wayne worked for 5 years as an Investment Banker. He worked for four years for Lehman Brothers in the Healthcare Investment Banking Group, mostly in London. After leaving Lehman Brothers as a Director in June 2008, Wayne joined UniCredit Markets and Investment Banking Division, and was based in their Tel Aviv office. Wayne holds an MBA from the Wharton School of the University of Pennsylvania. He is a Chartered Financial Analyst (CFA), and a qualified attorney in South Africa, and holds BCom and LLB degrees from the University of the Witwatersrand in Johannesburg, South Africa.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

BiondVax Pharmaceuticals

BiondVax Pharmaceuticals ("the Company"), a publicly-traded company (TASE: BNDX) based in Rechovot, Israel, is developing a proprietary, innovative Universal Influenza (" flu ") vaccine, the Multimeric-001 vaccine, with the potential to provide multi-season and multi-strain protection against most human Influenza virus strains, including both seasonal influenza strains as well as pandemic influenza strains, such as Swine flu and Avian flu . BiondVax 's proprietary technology utilizes a unique, proprietary combination of conserved epitopes from Influenza virus proteins to activate the immune system for a cross-protecting and long-lasting effect. BiondVax has recently successfully concluded a second Phase I/II clinical trial for its lead product, the Multimeric-001 vaccine. The vaccine has been shown to be safe and immunogenic in both Phase I/II clinical trials.